Treatment for E. coli Urinary Tract Infection (UTI)

First-Line Treatment Options for Uncomplicated UTIs

The Infectious Diseases Society of America recommends nitrofurantoin, fosfomycin, or trimethoprim-sulfamethoxazole (if local resistance is <20%) as first-line treatments for uncomplicated E. coli UTIs, with fluoroquinolones reserved as second-line options due to increasing resistance concerns 1
Trimethoprim-sulfamethoxazole is considered a first-line treatment option if local E. coli resistance is <20% and the patient has not used this antibiotic in the previous 3-6 months 1

The Infectious Diseases Society of America suggests checking local resistance patterns before selecting empiric therapy 1
For patients with recent antibiotic exposure (especially to trimethoprim-sulfamethoxazole), it is recommended to avoid that same class due to increased resistance risk 1

Oral fluoroquinolone (ciprofloxacin 500mg twice daily for 7 days) is recommended if local resistance <10% 1
Trimethoprim-sulfamethoxazole (160/800mg twice daily for 14 days) is recommended only if susceptibility is confirmed 1
If using oral β-lactams, it is recommended to start with an initial IV dose of ceftriaxone 1g or aminoglycoside 1

Initial IV therapy with fluoroquinolone, aminoglycoside (with/without ampicillin), extended-spectrum cephalosporin/penicillin, or carbapenem is recommended 1
Therapy should be tailored based on culture and susceptibility results 1

For recurrent UTIs, the American Urological Association considers prophylactic strategies, including post-coital antibiotics for premenopausal women with infection related to sexual activity 2
Treating asymptomatic bacteriuria in women with recurrent UTIs is not recommended, as it fosters antimicrobial resistance and increases recurrence episodes 2
Failing to obtain pre-treatment urine culture in patients with recurrent UTIs is a common pitfall to avoid 2

Using fluoroquinolones as first-line therapy for uncomplicated UTIs due to increasing resistance and risk of adverse effects is not recommended 1
Inadequate treatment duration for pyelonephritis (should be 7-14 days depending on antibiotic choice) is a common mistake 1
Using antibiotics with known high local resistance rates (>20%) for empiric therapy is not recommended 1

The American Academy of Pediatrics recommends parenteral options for febrile infants with UTI, including ceftriaxone 75 mg/kg every 24h, cefotaxime 150 mg/kg per day divided every 6-8h, and gentamicin 7.5 mg/kg per day divided every 8h, with a treatment duration of 7-14 days 3
For carbapenem-resistant E. coli (CRE), the Infectious Diseases Society of America recommends ceftazidime-avibactam 2.5g IV q8h, meropenem-vaborbactam 4g IV q8h or imipenem-cilastatin-relebactam 1.25g IV q6h, and single-dose aminoglycoside for simple cystitis due to CRE 4

The American Academy of Pediatrics recommends oral options for pediatric UTIs, including cefixime 8 mg/kg per day in 1 dose 3
For pediatric patients with febrile UTIs, renal and bladder ultrasonography should be considered to detect anatomic abnormalities 3

For multidrug-resistant (MDR) E. coli, the Infectious Diseases Society of America recommends considering local resistance patterns when selecting empiric therapy, with options including aminoglycosides and carbapenems 4